Dubai, UAE – April 30, 2026: Novo Nordisk today announced positive topline results from PIONEER TEENS, a phase 3a trial evaluating oral semaglutide for type 2 diabetes in children and adolescents aged 10–17 years with type 2 diabetes. Oral semaglutide demonstrated a superior reduction in HbA1c (a measure of blood sugar control) over placebo in the trial and showed a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials. Oral semaglutide is available today as Rybelsus® in the EU and US and will be available in the US as Ozempic® pill soon.

Dr. Motaz Azzam – senior pediatric endocrinology fellow – Al Jalila Children’s Hospital